Dexmedetomidine, a highly selective α2-adrenoceptor agonist, has sedative, anxiolytic,
analgesic, sympatholytic, and opioid-sparing properties and induces a unique sedative …

Objectives: We sought to evaluate dexmedetomidine efficacy in assuring comfort and
sparing conventional drugs when used for prolonged sedation (≥ 24 hr) in critically ill …

Abstract Rationale, Aims and Objectives The Withdrawal Assessment Tool (WAT‐1) is one of
the most widely used clinician‐reported outcome measures to evaluate iatrogenic …

Background Laparoscopic pain is related to the stretching of the peritoneum and peritoneal
irritation caused by insufflation of the parietal peritoneum with carbon dioxide. In 2017 …

Background. We report two pediatric cases of anticholinergic toxidrome, including the
youngest reported to date, in which standard therapeutic strategies were either …

Abstract Study Objective Withdrawal syndrome (WS) may be a critical drawback of opioid/
benzodiazepine weaning in children. The most effective intervention to reduce WS …

Considering that neonatal pain is a relevant matter given its implications and consequences,
many neonates, particularly those undergoing critical care, are subjected to analgo-sedation …

Background: Dexmedetomidine, an alpha 2 agonist, has emerged as a desirable sedative
agent in the pediatric intensive care unit due to its minimal effect on respiratory status and …

Background In Part I of this review, we outlined the study characteristics and methodologies
utilized in adaptive clinical trials reported in the literature from 2010–2020. Herein, the …

Sedation and analgesia are required on a daily basis for infants and children in the pediatric
intensive care unit (PICU). Regardless of the patient's age, cognitive level, underlying …